

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

**INSIDE INFORMATION
AND
RESUMPTION OF TRADING**

INSIDE INFORMATION

This announcement (the “**Announcement**”) is made by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

In relation to the recent media reports regarding Mr. Guo Guangchang (“**Mr. Guo**”), the Company’s non-executive director and the ultimate controlling shareholder, after making written enquiries to the Company’s controlling shareholder, Shanghai Fosun High Technology (Group) Co., Ltd.* (“**Fosun Group**”), the Company was notified according to the response, “Mr. Guo is currently assisting in certain investigations carried out by Mainland judiciary authorities. Mr. Guo may continue to take part in decision makings of Fosun Group’s major matters via appropriate means. The directors of Fosun Group are of the view that this investigation has not posed any material adverse impact on the financial or operation of Fosun Group. The operations of Fosun Group remain normal.”

Mr. Guo is the Company’s ultimate controlling shareholder and non-executive director, but he does not participate in the daily business operations of the Company. As at the date of the Announcement, the Company’s business operations are normal.

RESUMPTION OF TRADING

At the request of the Company, trading of shares of the Company (stock code: 02196) was halted with effect from 9:00 a.m. on Friday, 11 December 2015. Application has been made by the Company to The Stock Exchange of Hong Kong Limited for the resumption of trading of shares of the Company with effect from 9:00 a.m. on Monday, 14 December 2015.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Chairman

Shanghai, the People's Republic of China
11 December 2015

As at the date of this announcement, the executive Directors are Mr. Chen Qiyu and Mr. Yao Fang; the non-executive Directors are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Wang Pinliang, Ms. Kang Lan and Mr. John Changzheng Ma; and the independent non-executive Directors are Dr. Zhang Weijiong, Mr. Cao Huimin, Mr. Jiang Xian and Dr. Wong Tin Yau Kelvin.

* *for identification purposes only*